MOWOOT’s Post

Key insights from the Investival BioTech-HealthTech-MedTech event in London last week: - Major industry players are seeking highly differentiated technologies for acquisition. - Ageing patent portfolios are a significant concern for these players. - Speed and efficiency are pivotal in the early stages of development. - The majority of M&A deals are valued at over $250 million. - There is a trend towards indications with larger patient populations. - Areas like cardiovascular health and precision oncology stand out as critical areas with unmet needs. - Investor syndicates are encouraged to foster synergies for mutual benefit. - Notably, big players are showing interest in early-stage deals, not just in later stages. - Early-stage companies are advised to tap into the talent pool transitioning from larger corporations. - Highlighting compelling performance data is essential for enhancing visibility and attracting interest. - It is recommended that platform technologies be strategically segmented to optimize overall exit value. Overall, these trends are highly encouraging for ambitious young MedTech companies such as 4D Medicine Ltd and they reaffirm several key aspects of our investment proposition. #investival #medtechinvestment #SeriesA #SeriesB #Medtech

We're proud to be a #mediapartner of the LSX World Congress — Connecting #Innovation with #Capital. The #event takes place from 29–30 April in London, with 2000+ attendees joining. The 10th LSX World Congress gathers the founders and CEOs of innovative #biotech, #medtech and #healthtech #startups through to healthcare giants, and everyone in between. They attend alongside the sector’s most active #investors, #pharma, medtech and healthtech BD&L teams and R&D leaders. #LSXWorld brings together the people who are developing technologies, solutions and new business models to tackle the biggest healthcare challenges in the industry today, and helps answer the question; what’s next and how do we get there? Find out more 👉 https://lnkd.in/ddbtpquX LSX - partnering for Life Science eXecutives #messengersinscience

Verve Ventures was recently featured among the top techbio and drug discovery investors in Dealroom.co and Speedinvest's TechBio x Drug Discovery report which explores the vast potential of innovation in this field. “We believe that startups embracing the convergence of biology and engineering have the power to shape a future where healthcare is not only more cost-effective but also delivers superior patient outcomes,” says Xavier Mesnier, Principal at Verve. “Through AI-driven patient profiling, platform technologies, and enabling tools, techbio entrepreneurs are catalyzing a paradigm shift in healthcare, where data-driven insights revolutionize how we understand and combat disease." Read the full report: https://lnkd.in/d9BcvV2Q #techbio #drugdiscovery #health #drugdevelopment #futureofhealth #venturecapital

⭐️The Medici Effect ⭐️ Standing in front of the breathtaking Florence Cathedral, I can’t help but think of the Medici family and their incredible influence on fostering innovation. As Frans Johansson describes in, The Medici Effect, the collision of diverse ideas and disciplines can spark groundbreaking innovations. At the BioVentureHub we are embodying this very philosophy. By bringing together non-competitive, complementary skills, technologies, and competencies, we are creating an ecosystem where diversity fuels innovation. Just as the Medici family catalyzed the Renaissance, we are cultivating collaboration and cross-pollination of ideas that push the boundaries of what's possible in life science and biotech. Innovation thrives when diversity leads the way! #innovation #collaboration #BioVentureHub #MediciEffect #diversityandinclusion #biotech #lifesciences

🚀 How do we gear up our organisation to commercialise and scale, without losing our innovative core? Today, in the third module of our life science scaleup program #10xHealth, our expert Anna Brattström from Lund University School of Economics and Management guided our 10xHealth companies through frameworks and tools relating to organising people, processes and organisational structures that are foundational for growth, managing the tension between explorative and exploitative phases of a company’s journey, as well as the shift from a focus on science to a focus on business.   📈 The #10xHealth program is targeted towards life science companies with the ambition to grow and scale. It is jointly developed by SmiLe Venture Hub and Medicon Village and co-financed by the European Regional Development Fund.    🌟 Companies participating in the 2024 pilot include: Paindrainer AB, Iconovo AB, Neola Medical, Uman Sense, Cyxone, NanoEcho AB   📧 If you're curious to find out more, feel free to reach out to Christine Dahlman Jacobsen or Sarah Lidé. #lifescience #scalingup

🚀 3 Tips to Stay Ahead in Biotech in the Healthcare Sector In the rapidly evolving world of biotech, staying ahead of the curve is crucial. Here are three essential tips to ensure you remain at the forefront of innovation: 1 - Embrace Innovation 🧬💡 2 - Focus on Robust Clinical Trials 📊✅ 3 - Build Strong Collaborations 🤝🌍 These insights come from our recent interview with Megan Baldwin, Founder and Chief Innovation Officer at Opthea. Click the link below to watch the full interview and gain more valuable insights: 🔗👉 https://lnkd.in/dSs2kzpC . . . #Biotech #Innovation #Healthcare #ClinicalTrials

📣 Save the date and learn more about convergence of Pharma, hospitals and startups to leverage healthcare data ! 👇

“Innovation is at the core of our business.” — Arjen Lemmen, VP of Corporate Development & Strategy at argenx. I'm happy to share my latest article for BiotechNews & Life Sciences that dives deep into Argenx, an example of biotech innovation emanating from Belgium! In my conversation with Arjen, we explored: • The remarkable transformation of Argenx from a platform company to a global leader with over 1,500 dedicated 'Argonauts' • The successful launch of VYVGART, a groundbreaking treatment for generalized myasthenia gravis • The integral role of innovation in shaping Argenx's culture and operational strategies • The significance of partnerships within the Belgian biotech ecosystem • How resilience and adaptability have allowed Argenx to navigate challenges in clinical trials and financing Argenx’s journey exemplifies how combining scientific rigor with entrepreneurial spirit can lead to groundbreaking advancements in healthcare.

We're thrilled to announce that our CEO, Mika Newton, will be a speaker at the upcoming Bio-IT World Investor Conference. Mika will participate in a panel discussion titled "Empowering Innovation: Build vs. Buy in Data Science and Engineering." 🔍 𝗣𝗮𝗻𝗲𝗹 𝗗𝗶𝘀𝗰𝘂𝘀𝘀𝗶𝗼𝗻 𝗛𝗶𝗴𝗵𝗹𝗶𝗴𝗵𝘁𝘀: This engaging session will dive deep into biotech investment strategies, spotlighting the role of data science in the success of startups and the strategic decision-making in larger pharmaceutical companies. It's an opportunity to explore the dynamics between developing in-house expertise versus leveraging external partnerships, the impact of outsourcing, and how technology assets are valued within the biotech/pharma landscape. A conversation for investors focused on fostering growth in this sector. 📅 𝗠𝗮𝗿𝗸 𝗬𝗼𝘂𝗿 𝗖𝗮𝗹𝗲𝗻𝗱𝗮𝗿𝘀! Date: April 17, 2024 Time: 12:00 PM EST Omni Boston Hotel at the Seaport Boston, MA 🎙️ 𝗙𝗲𝗮𝘁𝘂𝗿𝗶𝗻𝗴 𝗘𝘀𝘁𝗲𝗲𝗺𝗲𝗱 𝗣𝗮𝗻𝗲𝗹𝗶𝘀𝘁𝘀: Dana Callow, Founder & Managing Partner, Boston Millennia Partners Tom Neyarapally, CEO and Co-Founder, Archetype Therapeutics, Inc. Miruna Sasu, President and CEO, COTA, Inc. Christina Vorvis, PhD, Director, AbbVie Ventures Xiaoying Wu, MD,MS, Vice President, Data Science & Digital Health, Johnson & Johnson Innovative Medicine Mika and the team of experts will provide important insights that promise to enrich our understanding of innovation management in the health sector. For more details on the panel and the event, visit: https://lnkd.in/dRnKKURy If you are attending the Bio-IT World Conference & Expo and want to learn more about the xCures Platform, feel free to contact Bryan Federowicz, who will be at the event. #BioITWorld #InvestorConference #DataScience #Biotech #PharmaInnovation #HealthTech

🌍 Exciting Developments in Biotech, Health, and Medtech! Our CEO, Lars Kongsbak, recently had the honor of presenting at the LSX Nordic Congress, where leaders across the life sciences industry gather to explore cutting-edge solutions shaping the future of healthcare. In his presentation, Lars showcased how #Samplix is leveraging advanced single-cell analysis technology to 'Break New Ground in Cell Analysis.' Our innovative solutions are democratizing single-cell research and transforming biotech. We are proud to be part of a community that fosters the growth, development, and internationalization of Nordic life sciences and healthcare innovation, and we look forward to connecting with investors and strategic partners who share our vision. LSX - partnering for Life Science eXecutives #LSXNordic #Biotech #LifeSciences #HealthcareInnovation #MedTech #StrategicPartnerships #InvestmentOpportunities #Growth #HealthcareTransformation #Leadership #Innovation